SteinCares and Shilpa Biologicals Enter Strategic Licensing Agreement to Commercialize Biosimilar in Latin America

manufacturing-news
Image Courtesy: Pixabay

SteinCares and Shilpa Biologicals Pvt Ltd have announced a strategic licensing agreement to commercialize a biosimilar therapy across Latin America. Under the terms of the agreement, SteinCares will hold exclusive rights to register, market and distribute the biosimilar throughout Latin America and the Caribbean. Shilpa Biologicals will complete product development and oversee long-term commercial manufacturing from its integrated biologics facility in Dharwad, Karnataka, India.

The collaboration combines Shilpa Biologicals’ expertise in biologics development and high-quality manufacturing with SteinCares’ established regional platform, which spans regulatory strategy, market access and commercialization capabilities across 30 countries in Latin America and the Caribbean. The partnership is designed to accelerate patient access to cost-effective specialty therapies in a region characterized by diverse and complex healthcare systems.

Mitchell Waserstein, Chief Executive Officer of SteinCares, said the agreement strengthens the company’s leadership in biosimilars and reinforces its role as a partner of choice for global biopharmaceutical companies seeking entry into Latin America. He noted that the combination of Shilpa’s development and manufacturing capabilities with SteinCares’ regional infrastructure will create scalable healthcare solutions and expand access to innovative treatments.

Dr. Sridevi Khambhampaty, Chief Executive Officer of Shilpa Biologicals, said the agreement marks the company’s entry into Latin America and reflects its commitment to expanding global access to safe, high-quality biologic therapies. She added that the collaboration supports long-term international licensing partnerships and establishes a foundation for future initiatives across key markets.

SteinCares is recognized as a leading specialty pharmaceutical company focused on improving access to innovative and affordable therapies in Latin America. With more than 45 years of combined industry experience, the company operates an integrated “one-stop-shop” model that spans licensing, regulatory approval, commercialization, market access and patient support programs. It has played a pioneering role in introducing biosimilars to the region and maintains a diversified portfolio across innovative medicines, biosimilars and complex generics.

Shilpa Biologicals, a subsidiary of Shilpa Medicare Limited, is a fully integrated biopharmaceutical company with therapeutic focus areas including immunology, oncology and ophthalmology. Operating as a hybrid CDMO and pharmaceutical organization, the company provides development and manufacturing services as well as ready-to-license formulations, supported by advanced technology platforms and a growing biosimilars pipeline. The agreement underscores both companies’ shared commitment to broadening patient access to high-quality biologic therapies across Latin America.